Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate

Nature Medicine

Volumn 3, Issue 8, 1997, Pages 866-871

  Chen, Yaping ^a   Maguire, Terry ^b   Hileman, Ronald E ^c   Fromm, Jonathan R ^c   Esko, Jeffrey D ^d   Linhardt, Robert J ^c   Marks, Rory M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c University of Iowa   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARAN SULFATE; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; DENGUE; DENGUE VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; VIRUS INFECTIVITY;

AMINO ACID SEQUENCE; ANIMALS; CERCOPITHECUS AETHIOPS; CHO CELLS; CRICETINAE; DENGUE VIRUS; GLYCOSAMINOGLYCANS; HEPARIN; HEPARITIN SULFATE; IMMUNOHISTOCHEMISTRY; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; RECEPTORS, VIRUS; SURAMIN; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRULENCE;

ANIMALIA; DENGUE VIRUS; FLAVIVIRIDAE; FLAVIVIRUS;

EID: 0030764559     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0897-866     Document Type: Article

References (50)

1. Henchal, E.A. & Putnak, J.R. The dengue viruses. Clin. Microbiol. Rev. 3, 376-396 (1990).
2. Institute of Medicine (U.S.), Committee on Emerging Microbial Threats to Health. Emerging Infections: Microbial Threats to Health in the United States (National Academy Press, Washington, DC, 1992).
3. Halstead, S.B. The XXth century dengue pandemic: Need for surveillance and research. World Health Stat. Q. 45, 292-298 (1992).
4. Monath, T.P. Dengue: The risk to developed and developing countries. Proc. Natl. Acad. Sci. USA 91, 2395-2400 (1994).
5. World Health Organization. Dengue and dengue hemorrhagic fever. Report N117. (World Health Organization, Geneva, 1996).
6. Centers for Disease Control. Dengue Fever at the U.S.-Mexico Border, 1995-1996. Morbid. Mortal. Weekly Rep. 45, N39 (1996).
7. Tyler, K.L. & Fields, B.N. Pathogenesis of viral infections, in Fields Virology, 3rd edn., Vol. 1. (eds. Fields, B.N., Knipe, D.M. & Howley, P.M.) 173-217 (Lippincott-Raven, Philadelphia, 1996).
8. Wimmer, E. Introduction, in Cellular Receptors for Animal Viruses, (ed. Wimmer, E.) 1 -13 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1994).
9. Porterfield, J.S. Antibody-dependent enhancement of viral infectivity. Adv. Virus. Res. 31, 335-355 (1986).
10. He, R.-T. et al. Antibodies that block virus attachment to Vero cells are a major component of the human neutralizing antibody response against dengue virus type 2. J. Med. Virol. 45, 451-461 (1995).
11. Rice, C.M, Flaviviridae: The viruses and their replication, in Fields Virology, 3rd edn., Vol. 1. (eds. Fields, B.N., Knipe, D.M. & Howley, P.M.) 931-959 (Lippincott-Raven, Philadelphia, 1996).
12. Chen, Y., Maguire, T. & Marks, R.M. Demonstration of binding of dengue virus envelope protein to target cells. J. Virol. 70, 8765-8772 (1996).
13. Couchman, J.R. & Woods, A. Structure and biology of pericellular proteoglycans. in Cell Structure and Extracellular Glycoconjugates, Vol. 1. (eds. Roberts, D.D. & Mecham, R.P.) 33-82 (Academic Press, New York, 1993).
14. Rostand, K.S. & Esko, J.D. Microbial adherence and invasion through proteoglycans. Infect. Immun. 65, 1-8 (1997).
15. Thompson, L.D., Pantoliano, M.W. & Springer, B.A. Energetic characterization of the basic fibroblast growth factor-heparin interaction: Identification of the heparin binding domain. Biochemistry 33, 3831-3840 (1994).
16. Fromm, J.R., Hileman, R.E., Caldwell, E.E., Weiler, J.M. & Linhardt, R.J. Differences in the interaction of heparin with arginine and lysine and the importance of these basic amino acids in the binding of heparin to acidic fibroblast growth factor. Arch. Biochem. Biophys. 323, 279-287 (1995).
17. Bernfield, M. et al. Biology of syndecans. Annu. Rev. Cell Biol. 8, 365-393(1992).
18. Toida, T., Imanari, T., Hileman, R.E., Fromm, J.R. & Linhardt, R.J. Structural differences in heparan sulfates from different tissues and species. Biochem. J. 322, 499-506 (1997).
19. Linhardt, R.J. & Toida, T. Heparin oligosaccharides-new analogs development and application, in Carbohydrates as Drugs (eds. Witczak, Z.B. & Nieforth, K.A.) 277-341 (Marcel Dekker, New York, 1997).
20. Pervin, A., Gallo, C, Jandik, K.A., Han, X.J. & Linhardt, R.J. Preparation and structural characterization of large heparin-derived oligosaccharides. Glycobiology 5, 83-95 (1995).
21. Toida, T., Hileman, R.E., Smith, A.E., Vlahova, P.I. & Linhardt, R.J. Enzymatic preparation of heparin oligosaccharides containing antithrombin III binding sites. J. Biol. Chem. 271, 32040-32047 (1996).
22. Linhardt, R.J. Analysis of glycoconjugates. in Current Protocols in Molecular Biology, Vol. 2. (ed. Varki, A.) 17.13.17-17.13.32 (Wiley Interscience, Boston, 1994).
23. Bame, K.J. & Esko, J.D. Undersulfated heparan sulfate in a Chinese hamster ovary cell mutant defective in heparan sulfate N-sulfotransferase. J. Biol. Chem. 264, 8059-8065 (1989).
24. Esko, J.D. et al. Inhibition of chondroitin and heparan sulfate biosynthesis in Chinese hamster ovary cell mutants defective in galactosyltransferase I. J. Biol. Chem. 262, 12189-12195 (1987).
25. Lidholt, K. et al. A single mutation affects both N-acetylgucosaminyltransferase and glucuronosyltransferase activities in a Chinese hamster ovary cell mutant defective in heparan sulfate biosynthesis. Proc. Natl. Acad. Sci. USA 89, 2267-2271 (1992).
26. Esko, J.D., Stewart, T.E. & Taylor, W.H. Animal cell mutants defective in glycosaminoglycan biosynthesis. Proc. Natl. Acad. Sci. USA 82, 3197-3201 (1985).
27. Baeuerle, P.A. & Huttner, W.B. Chlorate-a potent inhibitor of protein sulfation in intact cells. Biochem. Biophys. Res. Commun. 141, 870-877 (1986).
28. Raake, W., Klauser, R.J., Elling, H. & Meinetsberger, E. Anticoagulant and antithrombotic properties of synthetic sulfated bis-lactobionic acid amides. Thromb. Res. 56, 719-730 (1989).
29. Sternbergh, W.C., Sobel, M. & Makhoul, R.G. Heparinoids with low anticoagulant potency attenuate postischemic endothelial cell dysfunction. J. Vasc. Surg. 21, 477-483 (1995).
30. Mohan, P., Hopfinger, A.J. & Baba, M. Naphthalenedisulfonic acid derivatives as potential anti-HIV agents: Chemistry, biology and molecular modeling of their inhibition of reverse transcriptase. Antiviral Chem. Chemother. 2, 215-222 (1991).
31. Cardin, A.D. & Weintraub, H.J. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 9, 21-32 (1989).
32. Faham, S., Hileman, R.E., Fromm, J.R., Linhardt, R.J. & Rees, D.C. Heparin structure and interactions with basic fibroblast growth factor. Science 271, 1116-1120 (1996).
33. Chen, W.-B. & Maguire, T. Nucleotide sequence of the envelope glycoprotein gene of a dengue-2 virus isolated during an epidemic of benign dengue fever in Tonga in 1974. Nucleic Acids Res. 18, 5889 (1990).
34. Rey, F.A., Heinz, F.X., Mandl, C., Kunz, C. & Harrison, S.C. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375, 291-298 (1995).
35. Peitsch, M.C. ProMod and Swiss-Model: Internet-based tools for automated comparative protein modelling. Biochem. Soc Trans. 24, 274-279 (1996).
36. Bork, P., Holm, L. & Sander., C. The immunoglobulin fold. Structural classification sequence patterns and common core. J. Mol. Biol. 242, 309-320 (1994).
37. McClain, D.S. & Fuller, O. Cell-specific kinetics and efficiency of herpes simplex virus type 1 entry are determined by two distinct phases of attachment. Virology 198, 690-702. (1994).
38. Montgomery, R.L, Warner, M.S., Lum, B.J. & Spear, P. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NCF receptor family. Cell 87, 427-436 (1996).
39. Maccarana, M., Sakura, Y., Tawada, A., Yoshida, K. & Lindahl, U. Domain structure of heparan sulfates from bovine organs. J. Biol. Chem. 271, 17804-17810 (1996).
40. Jackson, T. et al. Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate. J. Virol. 70, 5282-5287 (1996).
41. Ortega-Barria, E. & Pereira, M.E. A novel T. cruzi heparin-binding protein promotes fibroblast adhesion and penetration of engineered bacteria and trypanosomes into mammalian cells. Cell 67, 411-421 (1991).
42. Ruoslahti, E. & Pierschbacher, M.D. New perspectives in cell adhesion: RGD and integrins. Science 238, 491-497 (1987).
43. Sanchez, I.J. & Ruiz, B.H. A single nucleotide change in the E protein of dengue virus 2 Mexican strain affects neurovirulence in mice. J. Gen. Virol. 77, 2541-2545 (1996).
44. Lin, B., Parrish, C.R., Murray, J.M. & Wright, P.J. Localization of a neutralization epitope on the envelope protein of dengue virus type 2. Virology 202, 885-890 (1994).
45. Jiang, W.R., Lowe, A., Higgs, S., Reid, H. & Could, E.A. Single amino acid codon changes detected in louping ill virus antibody-resistant mutants with reduced neurovirulence. J. Gen. Virol. 74, 931-935 (1993).
46. Jennings, A.D. et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J. Infect. Dis. 169, 512-518 (1994).
47. Holzmann, H., Heinz, F.X., Mandl, C.W., Cuirakhoo, F. & Kunz, C. A single amino acid substitution in envelope protein E of tick-borne encephalitis virus leads to attenuation in the mouse model. J. Virol. 64, 5156-5159 (1990).
48. Cecilia, D. & Could, E.A. Nucleotide changes responsible for loss of neuroinvasiveness in Japanese encephalitis virus neutralization-resistant mice. Virology 181, 70-77 (1991).
49. Reed, L.J. & Muench, H. A simple method of estimating fifty per cent end points. Am. J. Hygiene 27, 493-497. (1938).
50. Ojala, W.H. et al. Complexes of lysine, histidine and arginine with sulfonated azo dyes: Model systems for understanding the biomolecular recognition of glycosaminoglycans by proteins. J. Am. Chem. Soc. 118, 2131-2142 (1996).